scholarly journals STATE OF IMMUNITY IN PRESCHOOLERS WITH ACUTE RESPIRATORY VIRAL INFECTIONS ASSOCIATED WITH ADENOID VEGETATIONS

Author(s):  
Evgeniia Dmitrova ◽  
◽  
Oleksandr Smiyan ◽  
Viktoria Holubnycha ◽  
Kateryna Smiian ◽  
...  

Introduction. Acute respiratory infections are the most common infectious diseases worldwide among children of different age groups. Materials and methods. 59 children between the ages of 3 and 7 participated in the study. The first group included 22 patients with an acute respiratory viral infection, the second one consisted of 23 patients with acute respiratory viral infections associated with adenoid vegetation, and 14 apparently healthy children were included in the control group. Immunology research was conducted during the acute period of the disease. Statistical processing of received data was done with the standard statistical software EZR 1.41. Results. After the research, most of the patients with acute respiratory viral infections were identified an actual increase in CD3+, CD4+, CD8+, CD22+- cells and IgA, IgM in the blood serum. Simultaneously, in patients with acute respiratory viral infections associated with adenoid vegetation during the acute period, the increase in total lymphocytes was identified due to CD4+, CD8+, CD22+ cells and IgG. A comparative analysis of the study results of both groups of patients showed that children from the second group had a significantly higher level of CD3+- cells, while the CD22+- lymphocytes, IgA, IgM and IgG were significantly lower from the similar indicators of the first group. Conclusions. The acute period of the disease in children with acute respiratory viral infections, associated with adenoid vegetation, had an imbalance in both the cell and the immune system's humoral component

1982 ◽  
Vol 63 (2) ◽  
pp. 51-52
Author(s):  
V. A. Anokhin ◽  
A. D. Tsaregorodtsev

The aim of this work was to study the parameters of the components of the kinin blood system in children with severe forms of acute respiratory viral infections (ARVI) with neurotoxicosis syndrome. 55 children with ARVI (aged from 1 to 6 months - 14, from 6 months to 1 year - 18, from 1 to 3 years - 11, from 3 to 7 years - 12). 38 patients were admitted in the first three days of illness, 12 - on 4-5 days and 5 - at a later date. 30 children had a severe form of acute respiratory viral infection and 25 - moderate. Adenovirus infection was diagnosed in 14 patients, influenza - in 16, parainfluenza - in 7, MS-viral infection in 5, mixed viral infection - in 13. The control group consisted of 10 apparently healthy children.


Author(s):  
Е.Е. Краснова ◽  
В.В. Чемоданов ◽  
Е.Г. Кузнецова

Пневмония – острое инфекционно-воспалительное заболевание легких преимущественно бактериальной этиологии, характеризующееся выраженной в разной степени дыхательной недостаточностью, токсическими и респираторными нарушениями, локальными физикальными симптомами, а также инфильтративными изменениями на рентгенограмме. Заболеваемость внебольничными пневмониями повышается в октябре-декабре, достигая максимума в январе-апреле, коррелируя с сезонным повышением уровня острых респираторных вирусных инфекций. Схожесть симптомов дебюта пневмонии с проявлениями острых респираторных вирусных инфекций может привести к несвоевременной ее диагностике и, как следствие, к отсроченному началу лечения. Поэтому в период сезонной заболеваемости респираторными инфекциями должна повышаться настороженность врачей-педиатров в отношении внебольничной пневмонии. Антибактериальная терапия оказывает решающее влияние на прогноз пневмонии, поэтому при достоверном диагнозе или у больного в тяжелом состоянии с вероятным диагнозом ее следует начать незамедлительно. Выбор антибиотика в каждом случае внебольничной пневмонии проводят индивидуально с учетом природной активности препаратов в отношении предполагаемого возбудителя и их возможной приобретенной резистентности, тяжести и течения заболевания, наличия у пациента противопоказаний к использованию тех или иных антибиотиков. В статье приводятся сведения о диагностических критериях внебольничных пневмоний. Рассмотрены вопросы антибактериального лечения типичной нетяжелой пневмонии у детей разных возрастных групп амоксициллином с клавулановой кислотой и показана его эффективность. Результаты проведенного исследования позволяют заключить, что пероральное использование одного курса защищенного аминопенициллина эффективно при лечении типичной внебольничной нетяжелой пневмонии у детей разного возраста, о чем свидетельствует ликвидация основных клинических проявлений болезни в короткие сроки. Pneumonia is an acute infectious and inflammatory lung disease of predominantly bacterial etiology, characterized by respiratory failure, toxic and respiratory disorders, local physical symptoms, and infiltrative changes on the roentgenogram. The incidence of community-acquired pneumonia increases in October-December, reaching a maximum in January-April, correlating with the seasonal increase in the level of acute respiratory viral infections. The similarity of the symptoms of the onset of pneumonia with the manifestations of acute respiratory viral infections can lead to its untimely diagnosis and, as a consequence, to a delayed start of treatment. Therefore, during the period of seasonal morbidity with respiratory infections, the alertness of pediatricians in relation to community-acquired pneumonia should increase. Antibiotic therapy has a decisive influence on the prognosis of pneumonia, therefore, with a reliable diagnosis or in a patient in serious condition with a probable diagnosis, it should be started immediately. The choice of antibiotic in each case of community-acquired pneumonia is carried out individually, taking into account the natural activity of the drugs in relation to the alleged pathogen and their possible acquired resistance, the severity and course of the disease, the patient's contraindications to the use of certain antibiotics. The article provides information on the diagnostic criteria for community-acquired pneumonia. The issues of antibacterial treatment of typical non-severe pneumonia in children of different age groups with amoxicillin with clavulanic acid are considered and its effectiveness is shown. The results of the study allow us to conclude that the oral use of one course of protected aminopenicillin is effective in the treatment of typical community-acquired non-severe pneumonia in children of different ages, as evidenced by the elimination of the main clinical manifestations of the disease in a short time.


2019 ◽  
Vol 11 (3) ◽  
pp. 38-45
Author(s):  
S. A. Khmilevskaya ◽  
N. I. Zryachkin ◽  
V. E. Mikhailova

The aim: to study the etiological structure of acute respiratory infections in children aged 3 to 12 hospitalized in the early stages of the disease in the department of respiratory infections of the children’s hospital, and to reveal the features of their clinical course and the timing of DNA / RNA elimination of respiratory viruses from nasal secretions, depending on the method of therapy. Materials and methods: 100 children with acute respiratory infections aged 3 to 12 years were monitored. The nasal secrets on the DNA / RNA of respiratory viruses were studied by PCR. Depending on the method of therapy, patients were divided into 2 groups: patients of group 1 (comparison) received basic treatment (without the use of antiviral drugs), in patients of the 2nd group (main), along with basal therapy, the drug was used umifenovir in a 5-day course at the ageappropriate dosage. Results: In the etiologic structure of ARVI in children from 3 to 12 years, the leading place was taken by rhinovirus, influenza and metapneumovirus infections (isolated – 18%, 19% and 20% respectively, in the form of a mixed infection – 11%). The main syndromic diagnosis at the height of the disease was rhinopharyngitis. Complications were observed in 42% of cases, as often as possible with flu – 53% of cases. Features of metapneumovirus infection in children of this age group were: predominance of non-severe forms of the disease in the form of acute fever with symptoms of rhinopharyngitis, as well as a small incidence of lower respiratory tract infections. The use of the drug umiphenovir in children with acute respiratory viral infections of various etiologies contributed to significantly faster elimination of viral DNA / RNA from the nasal secretion, which was accompanied by a ecrease in the duration of the main clinical and hematological symptoms of the disease, a decrease in the incidence of complications, and reduced the duration of stay in hospital. Conclusion: application of modern molecular genetic methods of diagnostics made it possible to identify the leading role of influenza, metapneumovirus and rhinovirus infections in the etiology of acute respiratory viral infection in patients aged 3 to 12 years, and to determine a number of clinical features characteristic of this age group. The results of the study testify to the effectiveness of umiphenovir in the treatment of children with acute respiratory viral infections of various etiologies and allow us to recommend this drug as an effective and safe etiotropic agent.


1993 ◽  
Vol 74 (1) ◽  
pp. 22-24
Author(s):  
G. R. Khasanova ◽  
V. A. Anokhin ◽  
R. A. Urazaev ◽  
M. Yu. Yakovlev

As many as 101 patients with acute respiratory viral infections (ARVI) aged 3 months to 3 years are examined, of these in 51 patients the disease going with bronchoobstructive syndrome. According to the level of antiendotoxinal antibodies, plasma endotoxin and that connected by polymorphonuclear leukocytes, it is established that the acute period of acute respiratory viral infections with bronchoobstructive syndrome goes in the presence of pronounced cellularly connected endotoxinemy. The exact dependence is revealed between plasma endotoxin content and pronounced physical variations in respiratory organs in this form of the disease. Viral and bacterial nature of respiratory infections in children is confirmed by the assessment of the level of antiviral and antiendotoxinal antobodies. The data obtained allow suggesting the possible participation of endotoxin in genesis of bronchial obstruction in acute respiratory viral infections.


Author(s):  
Анна Александровна Зуйкова ◽  
Ольга Николаевна Красноруцкая ◽  
Юлия Александровна Котова ◽  
Даниил Юрьевич Бугримов

Острые респираторные вирусные инфекции (ОРВИ) представляют собой серьезную проблему для общественного здравоохранения во всем мире, вызывая значительную заболеваемость и смертность среди людей всех возрастных групп. Дети заражаются в среднем в два-три раза чаще, чем взрослые. Целью исследования является оценка эффективности препарата Деринат в комплексном лечении острых респираторных вирусных инфекций у детей дошкольного возраста в условиях амбулаторно-поликлинического приема. В исследование были включены дети в возрасте от 3 до 7 лет (включительно) не являющиеся школьниками, с клиническим диагнозом острая респираторная вирусная инфекция (ОРВИ), с симптомами, проявляющимися не длительнее 48 часов, не подвергавшихся противовирусной и иммуномодулирующей терапией в течение 30 дней до текущего посещения врача. В результате проведенного исследования установлено, что комплексное лечение ОРВИ у детей дошкольного возраста с применением препарата Деринат с первого дня терапии позволяет устранить отдельные симптомы ОРВИ значительно быстрее и эффективнее, чем при стандартных схемах терапии: ринорея и заложенность носа купируется на 2 день терапии, а гиперемия ротоглотки и отечность миндалин - на 3 день. Назначение изучаемого препарата в комплексном лечении ОРВИ в 2,4 раза повышает «Индекс здоровья» у дошкольников по сравнению с показателем при стандартных схемах лечения Acute respiratory viral infections are a serious public health problem worldwide, causing significant morbidity and mortality among people of all age groups. Children are infected on average two to three times more often than adults. The aim of the study is to evaluate the effectiveness of the drug Derinat in the complex treatment of acute respiratory viral infections in preschool children in outpatient settings. The study included children aged 3 to 7 years (inclusive) who are not schoolchildren, with a clinical diagnosis of acute respiratory viral infection, with symptoms that manifest no longer than 48 hours, who were not subjected to antiviral and immunomodulatory therapy for 30 days before the current doctor's visit. As a result of the study, it was found that the complex treatment of acute respiratory viral infections in preschool children with the use of the drug Derinat from the first day of therapy can eliminate individual symptoms of ARVI much faster and more effectively than with standard therapy regimens: rhinorrhea and nasal congestion are stopped on day 2 of therapy, and oropharyngeal hyperemia and tonsillar edema - on day 3. The administration of the studied drug in the complex treatment of acute respiratory viral infections increases the "Health Index" in preschool children by 2.4 times compared to the indicator for standard treatment regimens


2021 ◽  
Vol 16 (1) ◽  
pp. 20-26
Author(s):  
S.M. Nedelska ◽  
D.O. Vakula

Background. Atopic dermatitis (AD) is the most common allergic disease among children of young age. Severe forms of AD with skin bacterial and fungal overgrowth may be associated with features of the immune response in different age groups. Plenty of studies demonstrated not only polarization of the Th2 immune response in AD patients, but also the Th1 immune dysregulation. The purpose of this study was to investigate the features of the immune response in children with varying severity of atopic dermatitis. Materials and methods. The study included 85 children aged 3 months to 3 years with a verified diagnosis of AD, living in the Zaporozhzhia region. Twenty healthy children without atopy formed a control group. The patients were divided into groups depending on the severity of AD based on the SCORAD scale. The serum levels C3, C4–2, CD3+, CD19–, CD4+, CD8–, CD4–, CD8+, CD3–, CD56+, CD19+, CD14, CD45, IgA, IgM, IgG, IgE, С3, С4–2, phagocytic acti­vity of neutrophils, and proliferative activity of lymphocytes were measured by flow cyto­metry (Synevo). ELISA method was used to detect serum levels of IL-13 (ELISA Kit, Thermo Fisher Scientific, Austria). Statistical processing of the results was performed using the official software package Statistica 13.0. Results. The study revealed eosinophilia in 60 % of the children with a mild and moderate course of AD (Me 5.62 [3.64; 7.81]) and in 56 % of the children with a severe course (Me 6.18 [3.13; 9.42]). The children with a severe course of AD and low levels of IL-13, C3 had transient hypogammaglobulinemia and significantly lower le­vels of the C3 complement, increased levels of CD4+, CD8– with simultaneously decreased levels of CD4–, CD8+ compared with groups of the children with high levels of ­IL-13 (р < 0.05). Conclusion. The results suggest that severe forms of AD in children of the young age were associated with changes in the complement system and low levels of cytotoxic cells, transient hypogammaglobulinemia. It requires deeper research of the cascades of the immune response in children with AD.


2006 ◽  
Vol 5 (2) ◽  
pp. 119-126
Author(s):  
Ye. I. Kondratieva ◽  
L. A. Matveeva ◽  
Ye. Yu. Tyuteva ◽  
N. A. Ryzhakova ◽  
A. A. Terentieva ◽  
...  

The aim of the research was the investigation of prophylactic using the drug «Cycloferon». Influence of Cycloferon on acute respiratory viral infection and flu and on their clinical manifestations as well as on local immunity condition was assessed. We examined 124 children aged from 4 to 18 years. It was revealed that duration of acute respiratory viral infections as well as flu decreased and local immunity of the upper respiratory ways increased considerably in children taking Cycloferon. The abovementioned changes were observed both just after the treatment and in the follow-up period.


2018 ◽  
pp. 14-16 ◽  
Author(s):  
S. B. Krutikhina ◽  
E. A. Yablokova

Acute respiratory viral infections (ARVI) are leading in the structure of the general morbidity of the population. To date, more than 200 viruses that affect the respiratory tract and ENT organs are known [1]. The reservoir of ARVI pathogens is only human, the highest incidence is observed in the cold season [8]. It is also possible to infect several ARVI pathogens together, which is accompanied by a severe course of the disease and the addition of bacterial complications [6, 7]. To date, prevention and treatment of ARVI, both in adults and children, is one of the important tasks facing the medical community [1, 2]. The etiotropic therapy of most ARVI has not been developed, and the use of interferon preparations and interferon synthesis inducers has not proved their clinical efficacy [11]. As an alternative, bioregulatory agents that have proven their safety and clinical efficacy can be used [12]. The article presents numerous studies of clinical efficacy and safety of the bioregulatory drug Engystol in different age groups.


2020 ◽  
pp. 23-34
Author(s):  
O. A. Gizinger

The term «acute respiratory viral infections» refers to a group of diseases whose etiological agents are respiratory viruses, mainly affecting the epithelium of the upper respiratory tract. The article presents the results of studying the effectiveness of the drug Nobazit® in 32 patients with body temperature > 37.5 °C having at least one catarrhal symptom (cough, rhinitis, or sore throat) and one symptom of intoxication (chills, sweating, malaise, weakness, or headache) who consulted a doctor within the first 48 hours from the onset of symptoms of an acute respiratory viral infection. The use of the drug Nobazit® (enisamium iodide) allowed to reduce the severity of clinical manifestations, eliminate lymphopenia, normalize factors of innate and adaptive immunity, and restore the receptor landscape of peripheral blood lymphocytes. The registered clinical and immunological efficacy of the drug Nobazit® allows recommending its inclusion in the complex therapy of acute respiratory infections.


2020 ◽  
Vol 18 (3) ◽  
pp. 73-80
Author(s):  
E.V. Obraztsova ◽  
◽  
E.G. Golovacheva ◽  
L.V. Osidak ◽  
O.I. Afanasieva ◽  
...  

Influenza and acute respiratory viral infections (ARVI) remain a global health problem worldwide, and therefore the search for effective means of prevention and treatment of these diseases is extremely urgent. Objective. To evaluate the therapeutic efficacy and safety of a drug form of recombinant human IFN alpha-2b in combination with a complex of antioxidants (Viferon®-suppositories) in children with ARVI. Patients and methods. Clinical and laboratory studies were conducted in 100 children (toddlers up to 3 years old), hospitalized in St. Olga's children hospital No 4 with a diagnosis of influenza or ARVI. The etiology of diseases was established using serological methods and immunofluorescence analysis; the immune and interferon status was determined. VIFERON®-suppositories were used rectally daily in age-related dosages. The effectiveness of therapy was evaluated by comparative analysis of disease symptoms, as well as laboratory indicators – immune and interferon status. Results. The use of VIFERON® – suppositories contributed to reducing intoxication and catarrhal symptoms, speeding up the recovery time of patients. After the treatment, the children's ability to produce IFN-α and – γ, as well, as sIgA content in nasal secretions, increased, but there was no marked enhancement in serum IL-1β, IL-8 levels, whereas the children in the control group and in 30% of cases occurred to change them. The use of the medicine did not cause any complaints in patients and staff. Conclusion. Data from clinical and laboratory studies of children hospitalized for ARVI, whose therapy included the VIFERON® – suppositories, indicate a significant therapeutic effect of this medicine and restoration of the immune and interferon defense systems of patients. Keywords: children, acute respiratory viral infections, recombinant interferon α-2b, immune status, interferon status, antiviral therapy, cytokines IL-1β, IL-8, IL-10, TNF-α


Sign in / Sign up

Export Citation Format

Share Document